The danger in saying yes to Pascal Soriot’s pay rise at AstraZeneca

The Guardian

Lean Left

Mixed Factuality

Independent: Scott Trust Limited

The danger in saying yes to Pascal Soriot’s pay rise at AstraZeneca

Despite rebellion, approval of £18.7m package opens door to likelihood of US-style executive pay elsewhereIs Pascal Soriot, the chief executive of AstraZeneca, “massively underpaid”, as the chief investment officer of Florida-based GQG Partners, one of the company’s big shareholders, argued this week? Well, of course he’s not. Soriot has been paid £120m over the past decade, which is a helluva sum even for someone who has been brilliantly succes…